Search Results
Sep 08, 2026, 08:00 ET Azitra, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical and preclinical
More news about: Azitra, Inc.
Sep 03, 2026, 07:00 ET CytoSorbents Announces Reverse Stock Split
cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb-ATR is not yet granted or approved in either the U.S. or Canada.The Company has numerous
More news about: Cytosorbents Corp
Sep 02, 2026, 08:00 ET Atrium Therapeutics to Participate in Upcoming Investor Conferences
efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR-1072, the Company's pipeline includes ATR-1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.For more information
More news about: Atrium Therapeutics
Sep 02, 2026, 07:28 ET CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
additional real-world evidence planned for a new U.S. FDA De Novo submission for DrugSorb-ATR®Recent FDA Pre-Submission meetings provided constructive feedback on potential U.S. regulatory pathways for DrugSorb-ATR for separate applications for ticagrelor and direct oral anticoagulant removal
More news about: CytoSorbents Corporation
Aug 21, 2026, 08:00 ET Azitra, Inc. Regains Compliance with NYSE American Continued Listing Standards
data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical and preclinical
More news about: Azitra, Inc.
Aug 20, 2026, 18:23 ET Atrium Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.For more information
More news about: Atrium Therapeutics
Aug 13, 2026, 16:44 ET Atrium Therapeutics Reports Second Quarter 2026 Financial Results
Objection Letter for ATR 1072. FDA cleared Atrium's IND application for ATR 1072, allowing the Company to proceed with Corventis, a Phase 1/2 open-label, multicenter clinical trial designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of ATR 1072 in participants
More news about: Atrium Therapeutics
Aug 13, 2026, 08:00 ET Atrium Therapeutics Earns $15 Million Milestone Payment from Bristol Myers Squibb Under Global Cardiovascular Collaboration
efficient delivery to the heart, with the potential to overcome challenges associated with non-specific tissue delivery. Beyond ATR 1072, the Company's pipeline includes ATR 1086 for PLN (phospholamban) cardiomyopathy and two undisclosed research targets in rare cardiomyopathies.For more information
More news about: Atrium Therapeutics
Aug 12, 2026, 17:00 ET Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
data and topline results for the Phase 1b trial for our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, (iv) statements about our clinical and preclinical
More news about: Azitra, Inc.
Aug 06, 2026, 16:25 ET CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
U.S. Market Through DrugSorb-ATROur third value driver is obtaining FDA marketing approval for DrugSorb-ATR and opening what we believe represents one of the Company's most important long-term growth opportunities. DrugSorb-ATR addresses a significant unmet need in cardiac
More news about: Cytosorbents Corp
Aug 03, 2026, 02:01 ET IMPACT Therapeutics firma un acuerdo de licencia exclusiva con Pharmanovia
PARP1/2 senaparib (IMP4297), los inhibidores selectivos de PARP1 (IMP1734 e IMP1707, desarrollados conjuntamente con Eikon Therapeutics), el inhibidor de ATR (IMP9064), el inhibidor de WEE1 (IMP7068) y otros inhibidores de dianas de letalidad sintética.Nuestro crecimiento continuado se basa en una plataforma
More news about: IMPACT Therapeutics
Aug 03, 2026, 01:58 ET IMPACT Therapeutics unterzeichnet Exklusivlizenzvertrag mit Pharmanovia für Senaparib in Europa, dem Nahen Osten und Nordafrika, Australien und Neuseeland
zählen der PARP1/2-Inhibitor Senaparib (IMP4297), PARP1-selektive Inhibitoren (IMP1734 und IMP1707, gemeinsam mit Eikon Therapeutics entwickelt), ein ATR-Inhibitor (IMP9064), ein WEE1-Inhibitor (IMP7068) sowie zahlreiche weitere Inhibitoren, die auf synthetische Letalität abzielen.Unser kontinuierliches
More news about: IMPACT Therapeutics
Jul 31, 2026, 04:03 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.Our continued growth is powered by an
More news about: IMPACT Therapeutics
Jul 31, 2026, 03:48 ET IMPACT Therapeutics Signs Exclusive License Agreement with Pharmanovia for Senaparib in Europe, Middle East and North Africa, Australia and New Zealand
pipeline assets include the PARP1/2 inhibitor senaparib (IMP4297), PARP1-selective inhibitors (IMP1734 and IMP1707, co-developed with Eikon Therapeutics), ATR inhibitor (IMP9064), WEE1 inhibitor (IMP7068), and multiple other synthetic lethality target inhibitors.Our continued growth is powered by an
More news about: IMPACT Therapeutics
Jul 21, 2026, 01:00 ET RTX's Pratt & Whitney Canada signs PW127M maintenance agreement with Emerald Airlines
nearly five-year contract with Emerald Airlines to provide comprehensive maintenance, repair and overhaul (MRO) services for PW127M engines powering ATR 72-600 regional turboprops. Pratt & Whitney is an RTX (NYSE: RTX) business. "We worked with Emerald Airlines to develop a customized and inclusive
More news about: RTX
Jul 20, 2026, 17:58 ET Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.For
More news about: Atrium Therapeutics
Jul 20, 2026, 07:00 ET CytoSorbents to Report Second Quarter 2026 Financial Results and Recent Business Highlights
cardiothoracic surgery. The Company is actively pursuing regulatory approval of DrugSorb®-ATR with the U.S. FDA and will pursue regulatory approval with Health Canada with better visibility from the FDA. DrugSorb®-ATR is not yet granted or approved in either the U.S. or Canada.The Company has numerous
More news about: Cytosorbents Corp
Jul 15, 2026, 11:33 ET Azitra, Inc. Announces Breakthrough Repeat Dose and Anti-Wrinkle Ex Vivo Results for ATR-COSF Program, Demonstrating Increased Distribution and Elasticity
our ATR-12, (ii) the abstract detailing the Phase 1/2 clinical trial for our ATR-04 program, (iii) our provision of initial safety data and topline results for the Phase 1/2 clinical trial for our ATR-04 program, and (iv) statements about our clinical and preclinical programs, including ATR-COSF, and
More news about: Azitra, Inc.
Jul 14, 2026, 06:30 ET Atrium Therapeutics Announces FDA Clearance of Investigational New Drug Application for ATR 1072 for Treatment of PRKAG2 Syndrome
is anticipated in the second half of 2027.About ATR 1072ATR 1072, the company's lead product candidate, is a potentially disease-modifying treatment for PRKAG2 syndrome. Using Atrium's precision RNA delivery technology, ATR 1072 uses small interfering RNA (siRNA) to silence mutant
More news about: Atrium Therapeutics
Jul 07, 2026, 06:00 ET Sentry Aerospares Acquires AirStart
a leading global aviation aftermarket specialist focused on the exchange and leasing of rotable parts for commercial aircraft. With expertise across ATR, De Havilland Q400, MHI CRJ and Embraer platforms, AirStart offers tailored solutions to customers around the globe. Our core values drive us: respect,
More news about: Acorn Capital Management
Jun 23, 2026, 16:05 ET Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
non-specific tissue delivery. The Company's pipeline consists of two precision cardiology candidates, ATR 1072 for PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) syndrome and ATR 1086 for PLN (phospholamban) cardiomyopathy, and two undisclosed research targets in rare cardiomyopathies.For
More news about: Atrium Therapeutics
Jun 17, 2026, 08:00 ET Azitra, Inc. CEO Issues Letter to Shareholders Detailing Strategic Reorientation Initiatives and Outlook for 2026 and Beyond
Initiatives:ATR-COSF: Expansion into Cosmetic IngredientsOne of the most exciting initiatives enabled by the March financing is ATR-COSF, a recombinant filaggrin protein program designed for the cosmetic ingredient market.ATR-COSF originated from our ATR-01 research program,
More news about: Azitra, Inc.
Jun 16, 2026, 17:28 ET Azitra, Inc. to Present at 2026 BIO International Convention
EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic products
More news about: Azitra, Inc.
Jun 09, 2026, 09:00 ET New Codeshare Allowing Seamless Access to French Polynesia's Outlying Islands, Now in Effect!
departure to arrival.Passengers will travel aboard Air Tahiti Nui's Tahitian Dreamliner (Boeing 787-9) for international flights and Air Tahiti's ATR 72 aircraft for inter-island services.The activation of this codeshare agreement further strengthens the longstanding relationship between Air
More news about: Air Tahiti Nui
Jun 04, 2026, 16:05 ET Azitra Announces Adjournment of 2026 Annual Meeting and Information for Reconvened Meeting
for EGFRi associated rash, which impacts approximately 150,000 people in the U.S. Azitra has an open IND for its ATR-04 program in patients with EGFRi associated rash. The ATR-12 and ATR-04 programs were developed from Azitra's proprietary platform of engineered proteins and topical live biotherapeutic
More news about: Azitra, Inc.